2. Academic Validation
  3. Lipid-Optimized Sulfone-Bridged Cidofovir Prodrugs as Potent Antivirals Against Orthopoxviruses

Lipid-Optimized Sulfone-Bridged Cidofovir Prodrugs as Potent Antivirals Against Orthopoxviruses

  • J Med Chem. 2025 Nov 27;68(22):23867-23885. doi: 10.1021/acs.jmedchem.5c00863.
Baogang Wang 1,  Panpan Wei 1 2,  Shaowen Shi 3 4,  Zhu-Chun Bei 1,  Likun Xu 1,  Dongna Zhang 1,  Liangliang Zhao 1,  Kuo Cheng 1 2,  Qingbo Liu 1 5,  Hongquan Wang 1,  Xiao Li 3,  Zongzheng Zhao 3,  Qingguo Meng 2,  Yabin Song 1
Affiliations

Affiliations

  • 1 State Key Laboratory of Pathogen and Biosecurity, Academy of Military Medicine Sciences, Academy of Military Sciences, Beijing 100071, China.
  • 2 School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, Yantai 264005, China.
  • 3 Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
  • 4 Hebei Agricultural University, Baoding 071000, China.
  • 5 College of Pharmaceutical Science, Soochow University, Suzhou 215123, China.
PMID: 41255014 DOI: 10.1021/acs.jmedchem.5c00863
Abstract

The unprecedented global mpox outbreak highlights the urgent need for novel Orthopoxvirus antivirals. In this study, we rationally designed and synthesized a series of cidofovir (CDV) prodrugs conjugated with diverse lipid chains via sulfur-containing bridge moieties. Structure-activity relationship analyses identified the sulfone group as optimal, with a C2H4 linker and an approximately 20-atom chain length providing ideal Antiviral potency. Compound 13f exhibited Antiviral activity against vaccinia virus (VACV) comparable to that of the reference brincidofovir (BCV), while 13i displayed 8.2-fold enhanced potency. Both derivatives demonstrated superior potency against monkeypox virus (MPXV) compared to BCV. Stability tests in biorelevant media and pharmacokinetic evaluations confirmed favorable oral formulation characteristics for 13f and 13i. Notably, 13i exhibited a favorable safety profile and significant therapeutic efficacy in both VACV-challenged BALB/c and MPXV-challenged severe combined immunodeficiency mouse models. Through systematic lipid-chain optimization, we identified 13i as a promising Antiviral candidate with enhanced efficacy and favorable pharmaceutical properties.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z